Cogstate (ASX:CGS) is converting a record contract pipeline into visible growth, with backlog strength, a debt-free balance sheet, and a defensible niche in CNS trial technology driving an attractive asymmetric five-year setup.
Overview
Cogstate Limited is a specialized neuroscience technology company supplying digital cognitive assessment, rater training, and data quality solutions to pharmaceutical sponsors and clinicians. **The key investment case is that Cogstate sits in a mission-critical niche of CNS drug development and is now showing a step-change in commercial momentum**, with FY26 net sales contracts surging 115.7% to US$89.0 million and contracted future revenue reaching US$118.5 million as at 30 June 2026. Clinical Trials remains the core earnings engine, contributing more than 90% of revenue, while Healthcare provides high-margin licensing support through the Eisai partnership.
The business benefits from high switching costs, a deeply validated normative data asset, and workflow integration with Medidata, which is helping expand proposal volumes and win rates. Financially, 1H26 revenue rose 12% to US$26.92 million, NPAT increased 16% to US$4.5 million, and the company maintained a debt-free balance sheet with US$35.6 million of cash. **Valuation still looks supportive despite strong share price performance**, with a trailing P/E of 22.0x, a forward PEG of 0.66x, and consensus target price of AU$3.17 versus a post-update share price of AU$2.69. Near-term catalysts include FY26 audited results on 18 August 2026 and continued conversion of the enlarged backlog into FY27 revenue.